These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 24337217)
1. Sex differences in the incidence of chronic myeloid leukemia. Radivoyevitch T; Jankovic GM; Tiu RV; Saunthararajah Y; Jackson RC; Hlatky LR; Gale RP; Sachs RK Radiat Environ Biophys; 2014 Mar; 53(1):55-63. PubMed ID: 24337217 [TBL] [Abstract][Full Text] [Related]
4. The risk of chronic myeloid leukemia: can the dose-response curve be U-shaped? Radivoyevitch T; Kozubek S; Sachs RK Radiat Res; 2002 Jan; 157(1):106-9. PubMed ID: 11754648 [TBL] [Abstract][Full Text] [Related]
5. Accurate prediction of the age incidence of chronic myeloid leukemia with an improved two-mutation mathematical model. Lecca P; Sorio C Integr Biol (Camb); 2016 Dec; 8(12):1261-1275. PubMed ID: 27801472 [TBL] [Abstract][Full Text] [Related]
6. Risk and survival of chronic myeloid leukemia after breast cancer: A population-based study. Al-Husseini MJ; Mohamed HH; Saad AM; Gad MM; Atia M; Qaddoora U; Abushouk AI; El-Shinawi M Curr Probl Cancer; 2019 Jun; 43(3):213-221. PubMed ID: 30195804 [TBL] [Abstract][Full Text] [Related]
7. Biologically based risk estimation for radiation-induced CML. Inferences from BCR and ABL geometric distributions. Radivoyevitch T; Kozubek S; Sachs RK Radiat Environ Biophys; 2001 Mar; 40(1):1-9. PubMed ID: 11357705 [TBL] [Abstract][Full Text] [Related]
8. Estimation of the target stem-cell population size in chronic myeloid leukemogenesis. Radivoyevitch T; Ramsey MJ; Tucker JD Radiat Environ Biophys; 1999 Sep; 38(3):201-6. PubMed ID: 10525957 [TBL] [Abstract][Full Text] [Related]
14. Exposure to armament wastes and leukemia: a case-control study within a cluster of AML and CML in Germany. Kilian PH; Skrzypek S; Becker N; Havemann K Leuk Res; 2001 Oct; 25(10):839-45. PubMed ID: 11532515 [TBL] [Abstract][Full Text] [Related]
15. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein. Carlo-Stella C; Dotti G; Mangoni L; Regazzi E; Garau D; Bonati A; Almici C; Sammarelli G; Savoldo B; Rizzo MT; Rizzoli V Blood; 1996 Oct; 88(8):3091-100. PubMed ID: 8874208 [TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of variation of relative risk by age at exposure in the Japanese atomic bomb survivors. Little MP Radiat Environ Biophys; 2009 Aug; 48(3):253-62. PubMed ID: 19471953 [TBL] [Abstract][Full Text] [Related]
18. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280 [TBL] [Abstract][Full Text] [Related]
19. Occurrence of chronic lymphocytic leukemia in patients with chronic myelogenous leukemia. Bhattacharyya PK Indian J Pathol Microbiol; 2013; 56(3):188-9. PubMed ID: 24152491 [TBL] [Abstract][Full Text] [Related]
20. A model of chromosome aberration induction and chronic myeloid leukaemia incidence at low doses. Ballarini F; Ottolenghi A Radiat Environ Biophys; 2004 Sep; 43(3):165-71. PubMed ID: 15309385 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]